相似文献
1
Bradykinin, COVID-19, and Pancreatitis, a Personal Perspective.
Function (Oxf). 2021 Sep 3;2(5):zqab046. doi: 10.1093/function/zqab046. eCollection 2021.
2
Pathological events in experimental acute pancreatitis prevented by the bradykinin antagonist, Hoe 140.
Br J Pharmacol. 1993 Feb;108(2):405-11. doi: 10.1111/j.1476-5381.1993.tb12817.x.
3
The bradykinin antagonist CP-0597 can limit the progression of postischemic pancreatitis.
Immunopharmacology. 1996 Jun;33(1-3):243-6. doi: 10.1016/0162-3109(96)00066-5.
4
Effects of the bradykinin antagonist, icatibant (Hoe 140), on pancreas and liver functions during and after caerulein-induced pancreatitis in rats.
Naunyn Schmiedebergs Arch Pharmacol. 1995 Nov;352(5):557-64. doi: 10.1007/BF00169391.
5
[Bradykinin antagonism in ischemia and reperfusion of the pancreas].
Zentralbl Chir. 1996;121(5):412-22; discussion 422-3.
6
Bradykinin involvement in the aggravation of acute pancreatitis in rabbits.
Digestion. 1993;54(4):224-30. doi: 10.1159/000201041.
7
Effects of a bradykinin receptor antagonist (HOE140) on taurocholate-induced acute pancreatitis in rats.
Pancreas. 1996 Oct;13(3):283-8. doi: 10.1097/00006676-199610000-00011.
8
Calcium signalling in pancreatic stellate cells: Mechanisms and potential roles.
Cell Calcium. 2016 Mar;59(2-3):140-4. doi: 10.1016/j.ceca.2016.02.003. Epub 2016 Feb 28.
9
Role of substance P and bradykinin in acute pancreatitis induced by secretory phospholipase A2.
Pancreas. 2008 Jul;37(1):50-5. doi: 10.1097/MPA.0b013e3185d9b9b.
10
Inhibition of bradykinin B2 receptor preserves microcirculation in experimental pancreatitis in rats.
Am J Physiol. 1998 Jan;274(1):G42-51. doi: 10.1152/ajpgi.1998.274.1.G42.
引用本文的文献
1
Transient Receptor Potential Ankyrin 1 Channels in Inflammation and Cancer: Accelerators or Brakes?
Function (Oxf). 2022 Sep 17;3(5):zqac049. doi: 10.1093/function/zqac049. eCollection 2022.
本文引用的文献
1
The roles of calcium and ATP in the physiology and pathology of the exocrine pancreas.
Physiol Rev. 2021 Oct 1;101(4):1691-1744. doi: 10.1152/physrev.00003.2021. Epub 2021 May 5.
2
Evaluation of the efficacy and safety of icatibant and C1 esterase/kallikrein inhibitor in severe COVID-19: study protocol for a three-armed randomized controlled trial.
Trials. 2021 Jan 20;22(1):71. doi: 10.1186/s13063-021-05027-9.
3
A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm.
Elife. 2020 Jul 7;9:e59177. doi: 10.7554/eLife.59177.
4
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Cell. 2020 Apr 16;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052. Epub 2020 Mar 5.
5
Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure.
Pharmacol Rev. 2019 Oct;71(4):539-570. doi: 10.1124/pr.118.017129.
6
Bradykinin, a hypotensive and smooth muscle stimulating factor released from plasma globulin by snake venoms and by trypsin.
Am J Physiol. 1949 Feb;156(2):261-73. doi: 10.1152/ajplegacy.1949.156.2.261.
7
The cause of the vasodilatation accompanying activity in the submandibular salivary gland.
J Physiol. 1955 May 27;128(2):235-48. doi: 10.1113/jphysiol.1955.sp005302.
8
ROLE OF BRADYKININ IN THE DEVELOPMENT OF ACUTE PANCREATITIS.
Nature. 1964 Dec 19;204:1212-3. doi: 10.1038/2041212a0.
9
The mechanism of the functional hyperaemia in the submandibular salivary gland.
J Physiol. 1955 Aug 29;129(2):253-71. doi: 10.1113/jphysiol.1955.sp005351.
Zotero 插件